ClinicalTrials.Veeva

Menu

Alveolar-capillary Reserve After Exercise in Chronic Obstructive Pulmonary Disease (COPD) (COP-DTPA)

Rigshospitalet logo

Rigshospitalet

Status

Completed

Conditions

Chronic Obstructive Pulmonary Disease

Treatments

Other: Acute exercise bout on visit 2 and 3

Study type

Interventional

Funder types

Other

Identifiers

NCT06287476
H-23043870

Details and patient eligibility

About

It is unknown whether individuals with COPD exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea. The aim of this study is to investigate whether individuals with COPD exhibit an abnormal increase in alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary permeability with a concomitantly exacerbated increase in lung tissue mass.

Full description

It is unknown whether individuals with COPD exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea. The aim of this study is to investigate whether individuals with COPD exhibit an abnormal increase in alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary permeability with a concomitantly exacerbated increase in lung tissue mass. The study participants include a control group and a group with COPD (GOLD I-III). Participants are undergoing three study days: (1) Measurement of maximal aerobic capacity and lung function test, (2) lung tissue mass and alveolar-capillary permeability is measured at rest and again 2 hours later, immediately after the participant has exercised on a bicycle ergometer and (3) supine cardiac output and pulmonary capillary blood volume will be measured at rest and immediately after exercise.

Enrollment

32 patients

Sex

All

Ages

45 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria - individuals with COPD

  • Men and women
  • 45-80 years old
  • COPD (GOLD stage I to III)
  • Resting arterial oxygenation > 90%

Inclusion criteria - healthy controls

  • Men and women
  • 45-80 years old
  • Non-smokers
  • Normal lung function
  • Same sex, age (± 3 years) as the COPD group

Exclusion criteria - individuals with COPD

  • Symptoms of ischemic heart disease
  • Known heart failure
  • Symptoms of illness, including fever, within 2 weeks prior to the study
  • Pregnancy
  • • Known renal or liver diseaseActive smoking (within 3 weeks)

Exclusion criteria - healthy controls

  • Known chronic lung disease
  • Symptoms of ischemic heart disease
  • Known heart failure
  • Symptoms of illness, including fever, within 2 weeks prior to the study
  • Pregnancy
  • Known renal or liver disease
  • Active smoking (within 3 weeks)

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

32 participants in 2 patient groups

Control Group
Experimental group
Description:
This arm consist of only healthy participants (age (+/- 3 years) and sex matched to the COPD group), which will undergo three study visits
Treatment:
Other: Acute exercise bout on visit 2 and 3
COPD group
Experimental group
Description:
This arm consist of only COPD patients, which will undergo three study visits
Treatment:
Other: Acute exercise bout on visit 2 and 3

Trial contacts and locations

1

Loading...

Central trial contact

Ronan MG Berg, MD, DMSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems